Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Recruiting now · Phase 4

Conditions studied: Kidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)

In brief

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Key facts

Study ID

NCT07017270

Run by

Unity Health Toronto

People needed

100

Starts

2025-11-27

Expected to finish

2027-09-01

Last updated by the study team

2026-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18
• Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days
• confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin.
• Ability to provided informed consent or through their substitute decision maker

You may not qualify if…

• Type 1 DM
• Use of a GLP-1-RA within 30 days prior to screening
• Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)
• Confirmed pregnancy, women of childbearing potential
• Known hypersensitivity to GLP-1-RA
• Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months
• Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA

Where it is running

• Unity Health Toronto — Toronto, Ontario, Canada (enrolling)
• Unity Health Toronto — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.